VC-backed Tricida rolls out IPO
South San Francisco, California-based Tricida Inc, a developer of oral drug therapies that treat patients with chronic kidney disease, has raised about $222.3 million for its IPO after pricing its 11.7 million shares at $19 per share. The stock began trading June 28, 2018 on the NASDAQ under the ticker symbol "TCDA." Goldman Sachs, J.P. Morgan Securities LLC and Cowen and Company LLC are the lead underwriters. Tricida's pre-IPO backers include Wellington Management Company LLP, Venrock Healthcare Capital Partners, Cormorant Asset Management, OrbiMed, Longitude Capital, Sibling Capital Ventures, Limulus Venture Partners and Vivo Capital.
28 June 2018•2 mins read
